Posted on 10/26/17
Mylan Wins UK Court Ruling Related to Copaxone 40 mg/mL Patent
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United Kingdom's High Court of Justice has issued a decision in favor of Mylan and its European . . .
Posted on 10/26/17
GlaxoSmithKline Plc (GSK) Q3 2017 Results - Earnings Call Transcript
GlaxoSmithKline Plc (NYSE:GSK)Q3 2017 Earnings CallOctober 25, 2017 9:00 am ETExecutivesEmma Walmsley - GlaxoSmithKline PlcSimon Dingemans - GlaxoSmithKline PlcDavid Redfern - GlaxoSmithKline PlcBrian McNamara - GlaxoSmithKline . . .
Posted on 10/26/17
Celgene's GED-0301 Failure Offers A Peek At The Value Of Synergy's Dolcanatide
Celgene Corporation (NASDAQ:CELG), a global pharmaceutical company based in the mid-Atlantic, recently announced that the company has discontinuedtheir Phase 3 trial for their drug, GED-0301. GED-0301 . . .
Posted on 10/26/17
Is Pfizer Inc. a Buy?
Pfizer Inc. (NYSE:PFE) shares have risen around 12% this year, in step with the iShares US Pharmaceuticals index. With talk of another spinoff and strong sales . . .
Posted on 10/26/17
Better Buy: Johnson & Johnson vs. Pfizer
They're two of the oldest, largest, and most respected healthcare companies around. But one has made investors much happier than the other in recent years. Johnson . . .
Posted on 10/26/17
Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement
PARSIPPANY, N.J. and MALVERN, Pa., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has committed to invest up to $25 . . .
Posted on 10/25/17
MD Magazine and Contagion Expand Strategic Alliance Partnership with Jackson Health System
CRANBURY, N.J.--(BUSINESS WIRE)--MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, and Contagion®, an all-inclusive resource for infectious disease . . .
Posted on 10/25/17
In Case You Missed It, Johnson & Johnson Is Undergoing a Major Business Transformation
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is what you might call a staple stock. It's a common holding for growth, value, and income investors given that . . .
Posted on 10/25/17
Idera Pharmaceuticals Proposes Public Offering of Common Stock
CAMBRIDGE, Mass. and EXTON, Pa, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) (“Idera” or the “Company”) today announced that it intends to offer . . .
Posted on 10/25/17
After The Earnings, I Prefer Johnson & Johnson, But Procter & Gamble Is A Better Deal
I’ve been following the third earnings season with great attention. Since September, I’ve entered in the process of investing $100K in the stock market. To this . . .
Posted on 10/24/17
Celgene: Still A Great Pipeline, Despite A Setback
Celgene (CELG) is a very interesting biotechnology company with a truly long-term focus and tolerance for risk. While some large pharma names acquire promising companies which . . .
Posted on 10/24/17
Concentra and U.S. Healthworks to Merge
Select Medical Holdings Corporation (NYSE: SEM) and Dignity Health today announced the signing of a definitive agreement to combine Concentra Group Holdings, LLC, an occupational medicine and . . .
Posted on 10/24/17
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 23, 2017 it approved non-statutory stock options to purchase an aggregate of 31,000 shares of its . . .
Posted on 10/24/17
Immune Pharmaceuticals Closes $18M Public Offering of Stock
ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the . . .
Posted on 10/23/17
3 Things, October 21, 2017: Celgene's New Gamble, Pluristem Marches On ARS, Janssen Advances Their Rheumatology Program
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world . . .
Posted on 10/23/17
How Big of a Deal Is Celgene's Flop?
Celgene (NASDAQ:CELG) shuttered two GED-301 Crohn's disease trials this week after an interim look at data by independent monitors proved disappointing. The late-stage failure dings Celgene's . . .
Posted on 10/23/17
Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences
Gilead Sciences' (NASDAQ:GILD) recently approved Yescarta could be a billion-dollar blockbuster cancer-cell therapy, but the company could face stiff competition from Celgene(NASDAQ:CELG) someday. Celgene has successfully . . .
Posted on 10/23/17
Should You Avoid Celgene Stock After Its Big Pipeline Setback?
Even some of the biggest and best have things go wrong every now and then. Celgene(NASDAQ:CELG) has been the best-performing biotech stock over the last five . . .
Posted on 10/23/17
5 Key Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE:JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos. However, the stock market rewards investors . . .
Posted on 10/23/17
Can Teva Pharmaceutical's Dividend Even Survive?
Several big-pharma stocks boast high dividend yields. None of them, though, come close to the 7.5% yield that Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has recently claimed. . . .
Posted on 10/23/17
Antares Pharma Receives Complete Response Letter From the FDA for XYOSTED
EWING, N.J., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that today it has received a Complete Response Letter (CRL) from the U.S. . . .
Posted on 10/20/17
Johnson & Johnson Does It Again
I’ve been very upbeat on Johnson & Johnson (JNJ) lately and fortunately for me, that sentiment came at just the right time. JNJ has taken off . . .
Posted on 10/20/17
Is It Time To Take Profits On Johnson & Johnson?
I know some of you are likely going to aghast by this headline. But, it's almost Halloween, so I'm alright with that. I know that many . . .
Posted on 10/20/17
Immune Pharmaceuticals Prices $18,000,000 Public Offering
ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the . . .
Posted on 10/19/17
Johnson & Johnson: Time To Take Profits?
I know some of you are likely going to aghast by this headline. But, it's almost Halloween, so I'm alright with that. I know that many . . .

